Market Eyes LiveGLP-1, Obesity and Biotech Stocks, Rated
The obesity and metabolic drug market has become one of the largest single-product opportunities in pharmaceutical history, and it has pulled a wide set of biotech names along with it. This page ranks the incumbents alongside the clinical-stage challengers and the platform biotechs.
Every score below is free. 20 glp-1, obesity and biotech stocks scored on the same eight factors, updated as the data changes.
Ranked by composite score
Ranked highest to lowest by MELANY composite score, a 0 to 100 reading from eight factors. Each row links to the full breakdown and the live price. Ratings are a dated snapshot, most recently computed 2026-08-20.
These tiers are algorithmic research readings, not a recommendation to buy or sell any security, and not personalized investment advice. Ranking order is not a suggested purchase order.
What is in the app for these 20 companies
The score and the eight factors behind it are open on every company page. The trade plan is the part that is not: one suggested entry price per company, the stop, the targets, and an alert when a name enters its entry zone. That unlocks free when you create an account.
What changed in the past month
4 of 20 companies in this group have a scoring history going back a month, and 4 of those changed. All 4 are below: 4 lower.
- -8Vertex Pharmaceuticals Inc (VRTX): now flagged Runner!, a separate short-term momentum flag rather than a step up or down, with its score fell 8 points to 60.
- -5Regeneron Pharmaceuticals Inc (REGN): score fell 5 points to 66.
- -4Eli Lilly & Co. (LLY): score fell 4 points to 67.
- -3Amgen Inc (AMGN): score fell 3 points to 67.
Measured against each company's rating about 30 days ago. A tier change is reported as a move between named tiers; the score is what carries the direction. Runner is a short-term momentum flag, not a rung above or below any other tier.
What moves this group
For the incumbents, manufacturing capacity, payer coverage and pricing pressure matter more than trial news. For the clinical-stage names, a single trial readout can reset the entire valuation, which is why their catalyst factor dominates and their scores are volatile. Patent timelines and the arrival of oral formulations are the structural swing factors for the group.
Also searched as: GLP-1 stocks, weight loss drug companies, obesity drug makers, biotech shares.
How Market Eyes Live scores these companies
Every company on this page is scored by MELANY, our own engine, which reads regulatory filings and market data and produces a composite score from 0 to 100 across eight factors: valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile and macro fit.
Each score maps to a conviction tier rather than a buy or sell call. Established companies with enough financial history are judged on fundamentals. Pre-profit or thin-data companies are judged on a separate speculative path that leans on momentum and theme strength, because there are not enough fundamentals to read. That is why two names with similar scores can carry very different risk.
Frequently asked questions
Which companies have approved obesity drugs?
A small number of large pharmaceutical companies do. The remainder of this list is clinical-stage or platform biotech with related programs, which is a materially different risk profile.
Why are clinical-stage biotech scores so volatile?
Because their value depends on binary trial outcomes rather than current earnings. Our engine scores them on a speculative path and weights the catalyst factor accordingly.
Is this a recommendation?
No. These are algorithmic research outputs, not personalized investment advice, and not a recommendation to buy or sell any security.
Free account, no card. The scores stay free; the entry prices unlock.